Externalized Immune System (EXIS™) Platform Applications
Prellis’ proprietary, industry-leading two-photon 3D printing technology supports large, complex tumor co-culture systems mimicking tumor microenvironments, enabling the interrogation of interactive biological systems for uniquely relevant prioritization of immuno-oncology therapeutics.
Harnessing the power of the human immune system to build next generation medicines.
Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development.
3D printed lymph nodes advance drug discovery and development
Prellis’ Externalized Immune System (EXIS™) platform recreates human immunobiology in vitro in the form of lymph node organoids (LNOs™). 3D printed LNOs™ allow direct access to a fully functional human immune system for antibody discovery, immunogenicity evaluation, and vaccine development.